Introduction
Pharmacology is continually evolving as advances in molecular biology, genetics, computational science, biotechnology, and materials science create new ways to discover, develop, and deliver medicines. Emerging areas aim to improve therapeutic precision, understand individual variation, address previously difficult disease targets, and strengthen medicine safety. Some approaches are already used in clinical practice, while others remain experimental or are at early stages of development.
Major emerging areas
| Area | Description | Potential applications | Current status |
|---|---|---|---|
Precision medicine | Uses relevant biological, genetic, environmental, and clinical information to improve the selection and evaluation of treatments for individuals or defined patient groups. |
| Established in selected clinical areas, with continuing research and expansion into additional conditions. |
Pharmacogenomics | Studies how genetic variation influences drug response, including drug metabolism, transport, target interactions, and susceptibility to adverse effects. |
| Clinically implemented for selected gene-drug relationships, while many proposed applications still require stronger evidence. |
Artificial intelligence in drug discovery | Uses computational methods and machine learning to analyze biological and chemical data and support the identification and prioritization of drug candidates. |
| An active research and development area; computational predictions require experimental and clinical validation. |
Biological medicines | Uses therapeutic substances produced through or derived from biological systems, including proteins, antibodies, and other complex molecules. |
| Many biological medicines are established therapies, with new classes and applications continuing to develop. |
Advanced drug-delivery systems | Develops formulations and technologies designed to improve the location, timing, or pattern of drug delivery. |
| Some technologies are established, while many advanced platforms remain under investigation. |
Nanomedicine | Applies nanoscale materials and systems to medicine, including drug delivery, imaging, and diagnostic applications. |
| Several nanomedicine products have reached clinical use, while many proposed applications remain experimental. |
Gene and RNA-based therapies | Uses genetic material or molecular systems to alter gene expression, supply functional genetic information, or influence disease-related biological pathways. |
| Some therapies are authorized for specific conditions, while many approaches remain in clinical research. |
Cell-based therapies | Uses living cells as therapeutic products or as part of a treatment strategy. |
| Some cell-based therapies are established for defined indications, while other applications require further evidence. |
Microbiome-related pharmacology | Investigates how microorganisms living in and on the human body influence drug metabolism, therapeutic responses, and disease processes. |
| A developing research field with many mechanisms and clinical applications still under investigation. |
Organ-on-chip and advanced biological models | Uses engineered microphysiological systems that reproduce selected features of human tissues or organs. |
| An expanding research area with potential to complement conventional experimental models. |
Digital and computational developments
| Technology | Description |
|---|---|
Molecular modeling | Uses computational representations of molecules and biological targets to investigate possible interactions. |
Systems pharmacology | Combines biological networks, mathematical models, and experimental data to understand drug effects across interconnected systems. |
Pharmacometric modeling | Uses quantitative mathematical models to describe relationships among drug exposure, biological response, and patient characteristics. |
Real-world data analysis | Uses health information from routine practice and other sources to investigate medicine use and outcomes, with careful attention to data quality and bias. |
Future research priorities
Develop safer and more selective therapeutic agents.
Improve treatments for rare and complex diseases.
Understand genetic and environmental influences on drug response.
Improve drug delivery to difficult-to-reach tissues.
Develop better models for predicting human drug responses.
Improve detection and prevention of adverse drug reactions.
Strengthen equitable access to effective and quality-assured medicines.
Improve reproducibility, transparency, and responsible use of research technologies.
Challenges and limitations
| Challenge | Description |
|---|---|
Scientific validation | Promising laboratory or computational findings may not translate into clinical benefit. |
Safety and uncertainty | New therapeutic platforms can introduce unfamiliar risks that require careful evaluation. |
Cost and accessibility | Advanced medicines may be expensive or difficult to distribute equitably. |
Data privacy | Genetic and health-related data require appropriate privacy protection and governance. |
Regulatory complexity | Innovative products may require specialized evaluation of quality, safety, and effectiveness. |
Ethical considerations | Research involving genetic information, human participants, and advanced biological technologies requires careful ethical oversight. |
Responsible future development
Maintain rigorous scientific and clinical evaluation.
Validate computational predictions through suitable experiments.
Ensure appropriate ethical and regulatory oversight.
Protect sensitive biological and health information.
Evaluate long-term safety where relevant.
Promote equitable access to scientifically supported treatments.
Communicate uncertainty and limitations clearly.
Common misconceptions
| Misconception | Correction |
|---|---|
Artificial intelligence can independently prove that a new drug is safe and effective. | AI can support research, but candidate medicines require experimental, clinical, and regulatory evaluation. |
Precision medicine means every patient receives a completely unique medicine. | Precision medicine often uses validated patient characteristics to select or adapt treatments from available therapeutic options. |
All emerging pharmacological technologies are already clinically established. | Many approaches remain experimental and require further evidence before routine clinical use. |